

Express Mail Label No.: EV 330 994 745 US

Date of Deposit: October 23, 2003

Attorney Docket No. VPI/00-129-1 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Robert J. Davies, et al.

ASSIGNEE: Vertex Pharmaceuticals Incorporated

DIVISIONAL OF: 09/955,601

EXAMINER: Kahsay Habte

FILING DATE: HEREWITH

ART UNIT: 1624

FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

October 23, 2003

Cambridge, Massachusetts

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the


APPLICANTS: Robert J. Davies, et al.
U.S.S.N.: Not Yet Assigned

cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-129-1 DIV US.

Respectfully submitted,



Andrea L.C. Robidoux and Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6731
Fax: (617) 444-6483

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	October 23, 2003
	First Named Inventor	Robert J. Davies
	Group Art Unit	1624
	Examiner Name	Kahsay Habte
	Attorney Docket Number	VPI/00-129-1 DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	4,051,252	09/27/1977	Mayer, et al.			
	A2*	3,935,183	01/27/1976	Baron, et al.			
	A3*	3,133,081	05/12/1964	Lafferty, et. al.			
	A4*	3,998,951	12/21/1976	Harnish, et al.			
	A5*	4,493,726	01/15/1985	Brudeska, et al.			
	A6*	5,972,946	10/26/1999	Murata, et al.			
	A7	6,277,989	08/21/2001	Chakravarty, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*		2000-26421	Japan	25-Jan-2000		X
	B2*		WO 00/21955	PCT	20-Apr-2000		
	B3*		WO 00/39101	PCT	06-Jul-2000		
	B4*		WO 98/14450	PCT	09-Apr-1998		
	B5*		WO 95/15758	PCT	15-Jun-1995		
	B6*		WO 99/62518	PCT	09-Dec-1999		
	B7*		WO 93/22681	PCT	11-Nov-1993		
	B8*		WO 01/60816	PCT	23-Aug-2001		
	B9*		WO 02/18346	PCT	07-Mar-2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Medwid, J.B., et al., "Preparation of Triazolo[1,5-c] pyrimidines as Potential Antiasthma Agents", <i>J. Med. Chem.</i> , 33:1230-1241 (1990).
	C2*	Traxler, P., et al., "Use of Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4)Phenylamino)pyrazolo[3,4-d]pyrimidines", <i>J. Med. Chem.</i> , 40:3601-3616 (1997).
	C3*	Parnell, E.W., "2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroimidazole", <i>J. Chem. Soc.</i> , 2363-2365 (1959).
	C4*	Brunswick, D.J., et al., "Cyclic Amidines, Part XXII. ¹ Novel Isomerism of Disubstituted Tri-cycloquinazolines and Molecular Orientations in Carcinogenesis", <i>J. Chem. Soc.</i> , 19:2641-2647 (1970).
	C5*	Baig, G.U., et al., "Triazines and Related Products. Part 27 ¹ . Thermolysis of 4-Anilino-1,2,3-benzotriazines", <i>J. Chem. Soc. Perkin Trans. 1</i> (5):999-1003 (1984).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/955,601, filed September 14, 2001, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	October 23, 2003
	First Named Inventor	Robert J. Davies
	Group Art Unit	1624
	Examiner Name	Kahsay Habte
	Attorney Docket Number	VPI/00-129-1 DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	4,051,252	09/27/1977	Mayer, et al.			
	A2*	3,935,183	01/27/1976	Baron, et al.			
	A3*	3,133,081	05/12/1964	Lafferty, et al.			
	A4*	3,998,951	12/21/1976	Hamish, et al.			
	A5*	4,493,726	01/15/1985	Brudeska, et al.			
	A6*	5,972,946	10/26/1999	Murata, et al.			
	A7	6,277,989	08/21/2001	Chakravarty, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*		2000-26421	Japan	25-Jan-2000		X
	B2*		WO 00/21955	PCT	20-Apr-2000		
	B3*		WO 00/39101	PCT	06-Jul-2000		
	B4*		WO 98/14450	PCT	09-Apr-1998		
	B5*		WO 95/15758	PCT	15-Jun-1995		
	B6*		WO 99/62518	PCT	09-Dec-1999		
	B7*		WO 93/22681	PCT	11-Nov-1993		
	B8*		WO 01/60816	PCT	23-Aug-2001		
	B9*		WO 02/18346	PCT	07-Mar-2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Medwid, J.B., et al., "Preparation of Triazolo[1,5-c] pyrimidines as Potential Antiasthma Agents", <i>J. Med. Chem.</i> , 33:1230-1241 (1990).
	C2*	Traxler, P., et al., "Use of Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4)Phenylamino)pyrazolo[3,4-d]pyrimidines", <i>J. Med. Chem.</i> , 40:3601-3616 (1997).
	C3*	Parnell, E.W., "2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroimidazole", <i>J. Chem. Soc.</i> , 2363-2365 (1959).
	C4*	Brunswick, D.J., et al., "Cyclic Amidines, Part XXII. ¹ Novel Isomerism of Disubstituted Tri-cycloquinazolines and Molecular Orientations in Carcinogenesis", <i>J. Chem. Soc.</i> , 19:2641-2647 (1970).
	C5*	Baig, G.U., et al., "Triazines and Related Products. Part 27 ¹ . Thermolysis of 4-Anilino-1,2,3-benzotriazines", <i>J. Chem. Soc. Perkin Trans. 1</i> (5):999-1003 (1984).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/955,601, filed September 14, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.